Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5918378 | 0.92 | SLC6A9 (0.40) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3541961 | 0.86 | NPC1 (0.40) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3541958 | 0.86 | NPC1 (0.40) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3543072 | 0.84 | SLC6A9 (0.41) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3543076 | 0.84 | SLC6A9 (0.41) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3542194 | 0.83 | SLC6A9 (0.39) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3542190 | 0.83 | SLC6A9 (0.39) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3538754 | 0.81 | SLC6A9 (0.37) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL3538757 | 0.81 | SLC6A9 (0.37) | NPC1RAB9AGAALMNASLC6A9 | |
| SCHEMBL5918365 | 0.81 | SLC6A9 (0.38) | SLC6A9TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222317-A1 | Azetidine Derivatives as GlyT1 Inhibitors | GRIA1, GLRA1, GRIN1 | NPC1 115/4885RAB9A 654/4885GAA 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.